This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0897190008326105v1 22/2/166    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Pesaturo, K. A. Articles by Ramsey, E. Z. Search for Related Content Social Bookmarking                         What's this?

Pediatric Pulmonary Hypertension: A Pharmacotherapeutic Review

^* To whom correspondence should be addressed. E-mail: kimberly.pesaturo{at}mcphs.edu.

	Abstract

Pulmonary hypertension in children is a disorder associated with increased pulmonary vascular resistance and arterial pressure, decreased cardiac output, and right-sided cardiac dysfunction that is caused by numerous etiologies. Although treatment will vary with underlying cause, pharmacological treatment has historically included inhaled nitric oxide and prostacyclin analogues. Over the past several years new agents have been added to the treatment armamentarium, including phosphodiesterase V inhibitors (eg sildenafil) and endothelin antagonists (eg bosentan). Further, more agents are currently under investigation for pulmonary hypertension in children including immunosuppressives and other endothelin antagonist entities. Limitations to treatment include the availability of appropriate, robust pediatric pharmacological data and constraints with dosage forms.

First published on January 5, 2009, doi:10.1177/0897190008326105

Journal of Pharmacy Practice 2009;22:166.

A more recent version of this article appeared on April 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?